--- title: "HK Market Rotation: Tracking 10 Stocks from Semis to Clean Energy" type: "News" locale: "en" url: "https://longbridge.com/en/news/296894914.md" description: "Hong Kong equities are experiencing sector rotation, with investors hunting for yield and catalysts in defensive and niche sectors. We track recent developments across ASMPT, Sino Biopharmaceutical and eight other companies." datetime: "2026-08-25T10:12:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296894914.md) - [en](https://longbridge.com/en/news/296894914.md) - [zh-HK](https://longbridge.com/zh-HK/news/296894914.md) generator: "portal-rs" --- # HK Market Rotation: Tracking 10 Stocks from Semis to Clean Energy Hong Kong equities are witnessing a pronounced sector rotation, as capital shifts toward niche assets and defensive plays amid broader market volatility, according to fund flow data. This transition is bringing diverse segments from semiconductor packaging to nuclear energy and weight-loss drugs into sharper focus. ### ASMPT (0522.HK) Shares of ASMPT have faced recent downward pressure, mirroring the broader weakness in power semiconductor components. However, the company is targeting third-quarter revenues between **USD 630 million and USD 690 million**. Institutional interest remains a tailwind, with BlackRock raising its long position to **5.35%** in mid-July 2026, signaling enduring confidence in advanced packaging solutions. ### Beijing Energy Clean Energy (0579.HK) Beijing Energy Clean Energy has shown resilience year-to-date. The company secured approval for a **569.85 MW** wind power project in August 2026, marking a significant capacity expansion. Furthermore, it recently established a joint venture in Beijing to explore energy storage technologies and contract energy management. ### Sino Biopharmaceutical (1177.HK) The pharmaceutical sector got a boost from positive headline results in Moderna and Merck's personalized mRNA cancer therapy trials. Sino Biopharm is accelerating its transition from generics to innovative drugs, which now account for roughly **45%** of its revenue. In late August 2026, its self-developed **TQF6422** monoclonal antibody was approved for clinical trials, targeting the lucrative fat loss and muscle gain market. ### Zhejiang Shibao (1057.HK) Zhejiang Shibao, a key automotive steering system supplier, has tracked the broader auto-parts sector's performance recently. The company went ex-dividend in mid-August 2026 with a payout of **HKD 0.07** per share, underscoring steady operational cash flows. ### CGN Power (1816.HK) CGN Power has recently outperformed traditional utility peers. As of August 2026, the company operates **31 nuclear units** with another **19 under construction**. Its total installed capacity has reached **58.49 million kW**, providing high visibility for long-term power generation revenue. ### Weimob (2013.HK) SaaS providers continue to face headwinds, and Weimob has been consolidating at lower levels. The company is actively pursuing a SaaS+AI strategy, having launched its WAI model and a consumer-facing AI product, WIME, which analysts view as critical for reviving growth in its e-commerce and marketing software segments. ### Bank of Communications (3328.HK) Bank of Communications remains a stable high-yield play. Amid expectations of shifting interest rates, large state-owned commercial banks continue to draw steady Southbound trading inflows, driven by their reliable dividend distributions. ### JBM Healthcare (2161.HK) & Dongfang Electric Heating (1072.HK) In the consumer healthcare space, JBM Healthcare's branded medicines division continues normal operations, with shares moving in tandem with broader retail sentiment. Meanwhile, Dongfang Electric Heating has seen muted trading activity recently, lacking major idiosyncratic catalysts. ### Energy China (0918.HK) The infrastructure segment remains largely range-bound. Energy China has not reported any material business updates recently, with its performance largely dictated by macro-level infrastructure investment expectations. *This article does not constitute investment advice.* ### Related Stocks - [01072.HK](https://longbridge.com/en/quote/01072.HK.md) - [03328.HK](https://longbridge.com/en/quote/03328.HK.md) - [01057.HK](https://longbridge.com/en/quote/01057.HK.md) - [01816.HK](https://longbridge.com/en/quote/01816.HK.md) - [02161.HK](https://longbridge.com/en/quote/02161.HK.md) - [02013.HK](https://longbridge.com/en/quote/02013.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) ## Related News & Research - [CGN Releases Next-Gen of China’s Self-Developed Hualong One Nuclear Power Technology](https://longbridge.com/en/news/298274270.md) - [CGN Kicks Off Construction of Second Hualong One Reactor at Zhaoyuan Nuclear Plant](https://longbridge.com/en/news/298168023.md) - [CGN Power starts full construction of Zhaoyuan nuclear Unit 2 on Sept. 5, 2026](https://longbridge.com/en/news/298020416.md) - [Sino Biopharma reports Phase I data showing TQC3721 dry powder inhaler boosts COPD lung function in dose-ranging trial](https://longbridge.com/en/news/298202928.md) - [Sino Biopharm says FDA clears IND for TQB6426 GPC3 ADC trial in advanced tumors](https://longbridge.com/en/news/297915540.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**